Abstract
Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease. Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumour, metastatic disease is associated with poor prognosis and short-term survival. Here, we review the role of a multidisciplinary approach to treating patients with metastatic urothelial cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S228-S231 |
| Journal | Journal of the Canadian Urological Association |
| Volume | 3 |
| Issue number | 6 SUPPL. 4 |
| State | Published - 2009 |
| Externally published | Yes |
ASJC Scopus subject areas
- Urology
Fingerprint
Dive into the research topics of 'Management of metastatic urothelial cancer: The role of surgery as an adjunct to chemotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS